[go: up one dir, main page]

AR247217A1 - Un procedimiento para la preparacion de nuevos derivados de 5'-deoxi-fluorocitidina. - Google Patents

Un procedimiento para la preparacion de nuevos derivados de 5'-deoxi-fluorocitidina.

Info

Publication number
AR247217A1
AR247217A1 AR88312471A AR31247188A AR247217A1 AR 247217 A1 AR247217 A1 AR 247217A1 AR 88312471 A AR88312471 A AR 88312471A AR 31247188 A AR31247188 A AR 31247188A AR 247217 A1 AR247217 A1 AR 247217A1
Authority
AR
Argentina
Prior art keywords
substituted
formula
methyl
cyclic
deoxi
Prior art date
Application number
AR88312471A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of AR247217A1 publication Critical patent/AR247217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

PRODUCCION DE DERIVADOS DE 5'-DEOXI-5-FLUOROCITINA DE FORMULA (I), DONDE R1, R2, Y R3 SON H Y/O AL MENOS UN RADICAL FACILMENTE HIDROLIZABLE BAJO CONDICIONES FISIOLOGICAS, DE FORMULA: R4CO-R5OCO-O R6SCO-, DONDE R4 ES HIDROGENO, ALQUILO, CICLOALQUILO, OXOALQUILO, BENCILO SUSTITUIDO O NO, FENETILO, PICOLILO Y 3-INDOLILMETILO, O FENILO SUSTITUIDO O NO, NAFTILO, DIFENILILO, TIENILO, METILTIENILO, FURILO, NITROFURILO, PIRROLILO, METILPIRROLILO, IMIDAZOLILO PIRAZOLILO, PIRIDILO, METILPIRIDILO O PIRACINILO, Y R5 Y R6 SON ALQUILO O BENCILO SUSTITUIDO O NO, 1-FENILETILO, PICOLILO O 3-INDLILMETILO,ASI COMO HIDRATOS O SOLVATOS DE LOS COMPUESTOS DE FORMULA (II), DONDE R7 ES HIDROGENO O BENCILOXICARBONILO, FENICARBONILO, 2,2,2-TRICLOROETO-XI-CARBONILO, R8 Y R9 SON HIDROGENO O BENCILO SUSTITUIDO O NO, SILILO SUSTITUIDO O NO,ALILO,METOXIMETILO,(2-METOXIETOXI)METILO Y TETRAHIDROPIRANILO O R8 Y R9 JUNTOS,FORMAN ACETAL CICLIICO, CETAL CICLICO, CARBONATO CICLICO, ORTOESTER CICLICO Y 1,3-(1,1,3,3-TETR ISOPROPIL)DISILOXANDIILO CICLICO CON UN COMPUESTO DE FORMULA (III): XCOR4, DONDE X ES HALOGENO, ACILOXI, ALQUILOXICARBONILOXI, SUCCINIMIDOOXI, FTALIMIDOOXI, 4-NITROFENILO, AZIDO, 2,4,6-TRIISOPROPILBENCENSULFONILO Y DIETILOXIFOSFORILOXI Y R4 ES HIDROGENO, ALQUILO, 1-FENILETILO, BENCILO SUSTITUIDO O NO, FENETILO, PICOLILO Y 3-INDOLILMETILO, O FENILO, SUSTITUIDO O NO,NAFTILO,DIFENILILO, TIENILO, METILPIRROLILO, IMIDAZOLILO, PIRAZOLILO, PIRIDILO, METILPIRIDILO Y PIRACINILO O CON UN COMPUESTO DE FORMULA (IV): YCOR10, DONDE Y ES HALOGENO, Y R10 TIENE FORMULA:R5O-O R6S-, DONDE R5 Y R6 ES ALQUILO O BENCILO SUSTITUIDO O NO 1-FENILETILO, FENETILO, PICOLILO Y 3- INDOLILMETILO, SEGUIDO DE SER NECESARIO, DE SEPARACION DE UN RADICAL PROTECTOR.
AR88312471A 1987-11-17 1988-11-16 Un procedimiento para la preparacion de nuevos derivados de 5'-deoxi-fluorocitidina. AR247217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (1)

Publication Number Publication Date
AR247217A1 true AR247217A1 (es) 1994-11-30

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
AR88312471A AR247217A1 (es) 1987-11-17 1988-11-16 Un procedimiento para la preparacion de nuevos derivados de 5'-deoxi-fluorocitidina.

Country Status (34)

Country Link
US (1) US4966891A (es)
EP (1) EP0316704B1 (es)
JP (1) JPH0678350B2 (es)
KR (1) KR970000241B1 (es)
CN (1) CN1022688C (es)
AR (1) AR247217A1 (es)
AT (1) ATE124951T1 (es)
AU (1) AU619220B2 (es)
CA (1) CA1327358C (es)
CS (1) CS274486B2 (es)
DE (2) DE10199027I2 (es)
DK (1) DK170893B1 (es)
DZ (1) DZ1270A1 (es)
ES (1) ES2074429T3 (es)
FI (1) FI89804C (es)
GR (1) GR3017686T3 (es)
HU (1) HU199866B (es)
IE (1) IE883430L (es)
IL (1) IL88363A0 (es)
IS (1) IS1895B (es)
LT (1) LT2185B (es)
LU (1) LU90769I2 (es)
LV (1) LV5624A3 (es)
MC (1) MC1992A1 (es)
MX (1) MX173347B (es)
NL (1) NL300045I2 (es)
NO (2) NO171167C (es)
NZ (1) NZ226923A (es)
PH (1) PH25641A (es)
PT (1) PT89009B (es)
SU (1) SU1736342A3 (es)
UA (1) UA19333A (es)
YU (1) YU47122B (es)
ZA (1) ZA888428B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
IT1291983B1 (it) * 1997-05-23 1999-01-25 Pro Bio Sint Srl Prodcedimento per la preparazione di un derivato della desossiuridina
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
DK1706414T3 (da) 2003-12-22 2008-10-13 Hoffmann La Roche Fremgangsmåde til fluorcytidinderivater
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
CA2554686A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
JP2008542247A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
ES2384267T3 (es) * 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
AR064625A1 (es) 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
MX2009011255A (es) * 2007-04-20 2009-11-23 Reddys Lab Ltd Dr Proceso para preparar capecitabina.
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009088989A1 (en) * 2008-01-03 2009-07-16 Plus Chemicals, S.A. Process for the preparation of capecitabine
SI2310011T1 (sl) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
BRPI0916694B1 (pt) 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
CN102858791A (zh) * 2009-07-23 2013-01-02 台湾神隆股份有限公司 制备氟胞苷衍生物的方法
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
PT2900657T (pt) 2012-09-26 2020-05-07 Hoffmann La Roche Compostos cíclicos de éter-pirazol-4-il-heterociclil-carboxamida e métodos de utilização
CA2890359A1 (en) 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
US10000521B2 (en) 2013-03-15 2018-06-19 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
MX384144B (es) * 2016-06-28 2025-03-14 Cellix Bio Private Ltd Composiciones y métodos para el tratamiento del cáncer.
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
WO2019139920A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
KR20210057025A (ko) * 2018-08-03 2021-05-20 셀릭스 바이오 프라이빗 리미티드 암의 치료를 위한 조성물 및 방법
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
TW202241931A (zh) 2021-01-08 2022-11-01 美商斯特蘭德治療股份有限公司 表現構築體及其用途
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
DZ1270A1 (fr) 2004-09-13
YU209188A (en) 1990-08-31
NO2001013I2 (no) 2006-05-01
HK1003114A1 (en) 1998-10-09
EP0316704B1 (de) 1995-07-12
CS274486B2 (en) 1991-04-11
NL300045I2 (nl) 2002-01-02
NZ226923A (en) 1990-10-26
IS1895B (is) 2003-10-20
ES2074429T3 (es) 1995-09-16
CA1327358C (en) 1994-03-01
AU2516888A (en) 1989-05-25
HUT48267A (en) 1989-05-29
HU199866B (en) 1990-03-28
DK640388A (da) 1989-05-18
EP0316704A2 (de) 1989-05-24
NL300045I1 (nl) 2001-08-01
DE10199027I2 (de) 2002-01-31
FI89804C (fi) 1993-11-25
SU1736342A3 (ru) 1992-05-23
LU90769I2 (fr) 2001-07-02
IS3412A7 (is) 1989-05-18
ZA888428B (en) 1989-06-28
US4966891A (en) 1990-10-30
NO171167C (no) 1993-02-03
FI89804B (fi) 1993-08-13
EP0316704A3 (en) 1990-11-22
DK640388D0 (da) 1988-11-16
CN1022688C (zh) 1993-11-10
JPH0678350B2 (ja) 1994-10-05
PT89009B (pt) 1993-02-26
CS747588A2 (en) 1990-09-12
AU619220B2 (en) 1992-01-23
GR3017686T3 (en) 1996-01-31
PT89009A (pt) 1988-12-01
NO885106L (no) 1989-05-18
KR890008162A (ko) 1989-07-10
LT2185B (lt) 1993-10-15
MX173347B (es) 1994-01-03
NO171167B (no) 1992-10-26
DE10199027I1 (de) 2001-08-02
FI885329L (fi) 1989-05-18
IL88363A0 (en) 1989-06-30
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
CN1033183A (zh) 1989-05-31
JPH01153696A (ja) 1989-06-15
DE3854148D1 (de) 1995-08-17
KR970000241B1 (ko) 1997-01-08
ATE124951T1 (de) 1995-07-15
MX13836A (es) 1993-10-01
UA19333A (uk) 1997-12-25
PH25641A (en) 1991-08-21
YU47122B (sh) 1994-12-28
IE883430L (en) 1989-05-17
FI885329A0 (fi) 1988-11-17
NO885106D0 (no) 1988-11-16
DK170893B1 (da) 1996-03-04

Similar Documents

Publication Publication Date Title
AR247217A1 (es) Un procedimiento para la preparacion de nuevos derivados de 5'-deoxi-fluorocitidina.
ES433902A1 (es) Procedimiento para la preparacion de bencilaminas.
ES8106142A1 (es) Un procedimiento para la preparacion de un indol
ES2057754T3 (es) Un derivado de 1-piridilimidazol asi como su produccion y su uso.
ES476224A1 (es) Un procedimiento para la preparacion de compuestos derivadosde estilbeno
ES472099A1 (es) Procedimiento para la preparacion de derivados prostanoicos.
ES8405371A1 (es) Un procedimiento para la preparacion de derivados del indol.
ES2038623T3 (es) Procedimiento para preparar soluciones de oxazafosforinas con estabilidad mejorada.
MY103905A (en) Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same.
ES471245A1 (es) Un procedimiento para la preparacion de una composicion her-bicida a base de derivados de n'-fenil-n-metilurea
ES8703870A1 (es) Procedimiento para preparar compuestos de 5-alquil-1-fenil-2-piperazinoalquilpirazolin-3-ona.
ES474677A1 (es) Un procedimiento para la produccion de pirazinobenzosazeni- nos
RO87707A (ro) Procedeu pentru prepararea unor saruri de piridiniu
ES2054474T3 (es) Nuevas n-bencil-n'-fenil y -fenalquil-tioureas.
ES8502977A1 (es) Un metodo de preparar profarmacos de pilocarpina
ES471403A1 (es) Un procedimiento de preparacion de derivados de la tienopi- ridina
ES462890A1 (es) Procedimiento para la preparacion de 1-(n-acil-carbamoil)-2-cianazi-ridinas con efecto cancerostatico y estimulador de inmunidad.
ES8400743A1 (es) "procedimiento para la preparacion de compuestos de 1-fenilindazol-3-ona".
AR241194A1 (es) Compuestos de s-triazina con tres sustituyentes cargados positivamente,procedimiento para su preparacion y composiciones que los contienen
FR2499076B1 (es)
ES2001006A4 (es) Compuestos sustituidos de 2,6-piridina sustituida
GB2104515B (en) Sulphimines
ES469896A1 (es) Procedimiento para la obtencion de derivados de la hidroxi-4tiazolinationa-2
HUT53365A (en) Process for producing 1,8-benzonaphthyridine derivatives
ES8301963A1 (es) Un procedimiento para preparacion de nuevas piperidinoquinazolinas.